Trial Profile
A Study to Assess the Efficacy and Safety of Disease modifying treatments in Patients with Multiple Sclerosis in Real-life Set-up: The Austrian MS Treatment Registry (AMSTR)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2021
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 01 Nov 2021 Primary endpoint (annualized relapse rates (ARR) during treatment with FTY, DMF or TERI over 2 years after initiation of therapy) has been met, according to Results published in the Journal of Neurology.
- 01 Nov 2021 Results published in the Journal of Neurology
- 12 Oct 2018 Results (N=664) assessing efficacy, frequencies and reasons for treatment interruption of fingolimod, dimethyl fumarate or teriflunomide, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis